Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
1,954
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

Aldana Rossoa Department of Clinical Sciences, Division of Geriatric Medicine, Lund University, Lund, Sweden;b Diagnostic Radiology, Department of Translational Medicine, Lund University, Lund, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6603-2855
ORCID Icon,
Gunnar Juliussonc Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;d Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0002-7911-7265
ORCID Icon,
Fryderyk Lorenze Department of Oncology and Hematology, Umeå University Hospital, Umeå, Sweden
,
Sören Lehmannf Department of Medical Sciences, Division of Hematology, Uppsala University Hospital, Uppsala, Sweden
,
Åsa Derolfg Department of Hematology, Karolinska University Hospital, Huddinge, Sweden
,
Stefan Denebergg Department of Hematology, Karolinska University Hospital, Huddinge, Sweden
,
Martin Jädersteng Department of Hematology, Karolinska University Hospital, Huddinge, SwedenORCID Iconhttps://orcid.org/0000-0001-5217-3235
ORCID Icon,
Petar Antunovich Department of Hematology, Linköping University Hospital, Linköping, Sweden
,
Jörg Cammengah Department of Hematology, Linköping University Hospital, Linköping, SwedenORCID Iconhttps://orcid.org/0000-0001-5573-7542
ORCID Icon,
Lars Möllgårdi Department of Hematology, Sahlgrenska University Hospital, Gothenburg, SwedenORCID Iconhttps://orcid.org/0000-0002-0773-3325
ORCID Icon,
Lovisa Wennströmi Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden
,
Emma Ölanderj Department of Hematology, Sundsvall Hospital, Sundsvall, Sweden
,
Mats Ehingerk Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, Lund, Sweden
,
Linda Fogelstrandl Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;m Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenORCID Iconhttps://orcid.org/0000-0003-3698-8519
ORCID Icon,
Martin Höglundf Department of Medical Sciences, Division of Hematology, Uppsala University Hospital, Uppsala, SwedenORCID Iconhttps://orcid.org/0000-0003-2468-0226
ORCID Icon &
Vladimir Lj Lazarevicc Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;d Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0002-1782-4423
ORCID Icon show all
Pages 1973-1981 | Received 11 Dec 2020, Accepted 01 Feb 2021, Published online: 10 Mar 2021

References

  • Juliusson G, Hagberg O, Lazarevic VL, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134:1558–1561.
  • Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
  • Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:697–712.
  • Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–2333.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
  • Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017 May;102:865–873.
  • Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–1291.
  • Knowledge bank for cancer treatment - Regionala cancercentrum i samverkan. 2020. [cited 2020 Sep 23]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/aml/
  • Juliusson G, Antunovic P, Derolf Å, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–4187.
  • Juliusson G, Billström R, Gruber A, et al., for the Swedish Adult Acute Leukemia Registry Group. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20:42–47.
  • Delsing Malmberg E, Rehammar A, Pereira MB, et al. Accurate and sensitive analysis of minimal residual disease in acute myeloid leukemia using deep sequencing of single nucleotide variations. J Mol Diagn. 2019;21:149–162.
  • Grant S, Chen YQ, May S. Performance of goodness-of-fit tests for the Cox proportional hazards model with time-varying covariates. Lifetime Data Anal. 2014;20:355–368.
  • Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10:195–216.
  • Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189–1199.
  • Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890.
  • Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013 Nov 1;31:3889–3897.
  • Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36:1486–1497.
  • Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099–2107.
  • Ali NA, O'Brien JM, Jr Blum W, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110:96–102.
  • Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273–1283. 20
  • Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134:935–945.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.